Hubei Jumpcan Pharmaceutical (600566.SZ) Subsidiary Signs Exclusive Commercialization Agreement with Puqi Pharmaceutical

Stock News02-02

Hubei Jumpcan Pharmaceutical Co.,Ltd. (600566.SZ) announced that its wholly-owned subsidiary, Jichuan Pharmaceutical Group Co., Ltd. ("Jichuan Limited"), has entered into an exclusive commercialization agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. ("Puqi Pharmaceutical").

The agreement grants Jichuan Limited exclusive rights to commercialize Puqi Pharmaceutical's Pumeixitinib (PG-011) nasal spray in China for the duration of the collaboration.

Jichuan Limited will pay Puqi Pharmaceutical an exclusive commercialization rights fee of up to a maximum of RMB 100 million (including tax).

According to the announcement, Pumeixitinib (PG-011) is a JAK1/2 inhibitor with independent intellectual property rights, developed for the treatment of allergic rhinitis.

Upon completion of the transaction, the company will further enhance the diversity of its product pipeline, which is conducive to the sustainable development of its business.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1192368771?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-02 18:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192368771","market":"fut","top_or_hot":-1,"title":"Hubei Jumpcan Pharmaceutical (600566.SZ) Subsidiary Signs Exclusive Commercialization Agreement with Puqi Pharmaceutical","media":"Stock News","content":"<p>Hubei Jumpcan Pharmaceutical Co.,Ltd. (600566.SZ) announced that its wholly-owned subsidiary, Jichuan Pharmaceutical Group Co., Ltd. (\"Jichuan Limited\"), has entered into an exclusive commercialization agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. (\"Puqi Pharmaceutical\").</p>\n<p>The agreement grants Jichuan Limited exclusive rights to commercialize Puqi Pharmaceutical's Pumeixitinib (PG-011) nasal spray in China for the duration of the collaboration.</p>\n<p>Jichuan Limited will pay Puqi Pharmaceutical an exclusive commercialization rights fee of up to a maximum of RMB 100 million (including tax).</p>\n<p>According to the announcement, Pumeixitinib (PG-011) is a JAK1/2 inhibitor with independent intellectual property rights, developed for the treatment of allergic rhinitis.</p>\n<p>Upon completion of the transaction, the company will further enhance the diversity of its product pipeline, which is conducive to the sustainable development of its business.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hubei Jumpcan Pharmaceutical (600566.SZ) Subsidiary Signs Exclusive Commercialization Agreement with Puqi Pharmaceutical</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHubei Jumpcan Pharmaceutical (600566.SZ) Subsidiary Signs Exclusive Commercialization Agreement with Puqi Pharmaceutical\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-02 18:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hubei Jumpcan Pharmaceutical Co.,Ltd. (600566.SZ) announced that its wholly-owned subsidiary, Jichuan Pharmaceutical Group Co., Ltd. (\"Jichuan Limited\"), has entered into an exclusive commercialization agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. (\"Puqi Pharmaceutical\").</p>\n<p>The agreement grants Jichuan Limited exclusive rights to commercialize Puqi Pharmaceutical's Pumeixitinib (PG-011) nasal spray in China for the duration of the collaboration.</p>\n<p>Jichuan Limited will pay Puqi Pharmaceutical an exclusive commercialization rights fee of up to a maximum of RMB 100 million (including tax).</p>\n<p>According to the announcement, Pumeixitinib (PG-011) is a JAK1/2 inhibitor with independent intellectual property rights, developed for the treatment of allergic rhinitis.</p>\n<p>Upon completion of the transaction, the company will further enhance the diversity of its product pipeline, which is conducive to the sustainable development of its business.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0188","symbol_name":"融资融券","start_time":0,"source_url":"","article_id":"1192368771","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192368771","pubTimestamp":1770028508,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Hubei Jumpcan Pharmaceutical Co.,Ltd. (600566.SZ) announced that its wholly-owned subsidiary, Jichuan Pharmaceutical Group Co., Ltd. (\"Jichuan Limited\"), has entered into an exclusive...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","600566":"济川药业","BK0188":"融资融券","BK0239":"医药制造","BK0077":"质押式回购","BK1515":"抗疫概念","BK1161":"生物科技","BK0028":"国家队","BK1574":"生物医药B类股","BK0012":"证金概念","BK0201":"可转债","09939":"开拓药业-B","BK0187":"一线龙头"},"translate_title":"湖北跃普康制药（600566.SZ）子公司与普祺制药签署独家商业化协议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"600566":1,"09939":1},"content_text":"Hubei Jumpcan Pharmaceutical Co.,Ltd. (600566.SZ) announced that its wholly-owned subsidiary, Jichuan Pharmaceutical Group Co., Ltd. (\"Jichuan Limited\"), has entered into an exclusive commercialization agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. (\"Puqi Pharmaceutical\").\nThe agreement grants Jichuan Limited exclusive rights to commercialize Puqi Pharmaceutical's Pumeixitinib (PG-011) nasal spray in China for the duration of the collaboration.\nJichuan Limited will pay Puqi Pharmaceutical an exclusive commercialization rights fee of up to a maximum of RMB 100 million (including tax).\nAccording to the announcement, Pumeixitinib (PG-011) is a JAK1/2 inhibitor with independent intellectual property rights, developed for the treatment of allergic rhinitis.\nUpon completion of the transaction, the company will further enhance the diversity of its product pipeline, which is conducive to the sustainable development of its business.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1192368771","isCrawlerRequest":true}